A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

NCT06275620 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

X-Linked Retinitis Pigmentosa

Interventions

BIOLOGICAL: AGTC-501 (high dose and standard corticosteroid regimen)
BIOLOGICAL: AGTC-501 (low dose and standard corticosteroid regimen)
BIOLOGICAL: AGTC-501 (high dose and modified corticosteroid regimen)

Sponsor

Beacon Therapeutics